A pharmacokinetic study of mycophenolate mofetil in patients with myasthenia gravis
- Author:
Di CHEN
1
Author Information
- Publication Type:Journal Article
- Keywords: HPLC; Myasthenia gravis; Mycophenolate mofetil; Pharmacokinetics
- From: Chinese Pharmaceutical Journal 2016;51(7):579-582
- CountryChina
- Language:Chinese
- Abstract: OBJECTIVE: To investigate the pharmacokinetics of mycophenolate mofetil in patients with myasthenia gravis, and evaluate the correlation between plasma concentration and AUC. METHODS: Eight myasthenia gravis patients older than 18 years old with normal liver and renal function were included in this study. Blood samples were collected at 0, 1, 2, 3, 4, 6, 8, 10 h after the patients were continuously given oral mycophenolate mofetil 2 g · d for one week. Plasma concentrations of mycophenolate mofetil were determined by HPLC method and data analysis was done by WinNonlin program. RESULTS: The main pharmacokinetic parameters of mycophenolate mofetil were as follows; ρmax was (11.39±3.23) μg · mL-1, tmax was (1.5±0.8) h, AUC0-12h was (38.71±11.23) μg · h · mL-1. The ρ2 had the best correlation with AUC (r2=0.80) followed by ρ0 and ρ4 (r2= 0.75). CONCLUSION: The pharmacokinetics of mycophenolate mofetil has great inter-individual differences, but without significant difference with those in healthy volunteers and transplant patients. The ρ0 can be used for routine therapeutic drug monitoring because of convenience and feasibility.
